x.ilio Therapeutics

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.

Xilio was founded in 2016 and is headquartered in Waltham, Mass. For more information, please visit www.xiliotx.com


Team Member
more about
Therese Liechtenstein
Latest News Entry
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

• Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors

• Proceeds will advance XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4) into the clinic

• Two investigational new drug (IND) applications planned in 2021

Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC

Xilio Therapeutics today announced the presentation of preclinical data of its lead investigational therapies at the 35th Annual Meeting of The Society for Immunotherapy of Cancer (SICT 2020).

Xilio Therapeutics Appoints Paul J. Clancy to its Board of Directors

Mr. Clancy brings significant strategic, financial and operational leadership experience in the biotechnology and pharmaceutical industry

Xilio Therapeutics Appoints Martin H. Huber, M.D as Chief Medical Officer

To Lead XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA-4) into the Clinic while Xilio Continues to Advance its Tumor-Selective Cytokine Pipeline

all related news
all portfolio news